Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving Average - Time to Sell?

Key Points

• Shares of Achieve Life Sciences crossed above its 200-day moving average (200‑day MA $4.40) during Friday trading; the stock last traded around $4.38 on volume of 467,452, a technical move that could indicate short-term momentum.
• Wall Street shows a consensus Buy rating with an average target price of $14.67 (several firms at $12–$13), though coverage is mixed (2 Strong Buy, 3 Buy, 1 Sell).
• Achieve is a clinical-stage biotech developing cytisinicline for smoking cessation but remains unprofitable (last quarter EPS −$0.28; expected −$1.34 for the year) with a market cap of about $233M, while institutional and hedge-fund ownership has risen to roughly 33.5%.

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.40 and traded as high as $4.40. Achieve Life Sciences shares last traded at $4.38, with a volume of 467,452 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ACHV. Weiss Ratings raised Achieve Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, April 24th. HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Finally, Canaccord Genuity Group set a $13.00 price target on Achieve Life Sciences and gave the company a "buy" rating in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Achieve Life Sciences has a consensus rating of "Buy" and an average target price of $14.67.

Achieve Life Sciences Trading Down 0.2%

The company has a 50 day moving average of $3.92 and a two-hundred day moving average of $4.40. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.39 and a current ratio of 4.39. The stock has a market capitalization of $233.15 million, a PE ratio of -3.37 and a beta of 2.25.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.01). Sell-side analysts predict that Achieve Life Sciences, Inc. will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Achieve Life Sciences

Hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. increased its holdings in shares of Achieve Life Sciences by 18,747.4% in the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company's stock valued at $21,715,000 after purchasing an additional 4,346,011 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Achieve Life Sciences by 14.5% in the third quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company's stock valued at $7,755,000 after buying an additional 311,925 shares in the last quarter. Millennium Management LLC grew its stake in shares of Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company's stock valued at $6,755,000 after buying an additional 1,121,614 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at $2,652,000. Finally, Marshall Wace LLP grew its stake in shares of Achieve Life Sciences by 31.5% in the fourth quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company's stock valued at $5,066,000 after buying an additional 244,428 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company's stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.